Avipep is interested in partnering with companies that have proprietary antibody leads or novel targets and/or a focus on developing ADCs.

Avipep technology and capabilities:

1. Developing new Avibodies or reformatting them from existing antibodies
2. Creating Avibody ADC conjugates utilising a variety of conjugation strategies and cytotoxic payloads
3. Avibody development programmes centered around partner’s targets, linkers, payloads, etc.

Avipep can also out-license the platform for various clinical applications and/or out-license specific internally developed Avibodies for clinical development.

Download poster from World ADC, Oct 2019